Singapore — As global pharmaceutical companies grapple with soaring R&D costs, long development timelines and rising clinical failure rates, a new generation of Singapore-based biotech firms is positioning artificial intelligence as a structural solution rather than a technological add-on.

Among them is Nanyang Biologics, a home-grown deep-tech company that has been quietly building an AI-native drug discovery platform capable of compressing early-stage research timelines by months and significantly reducing cost inefficiencies across the discovery-to-development pipeline.

Drug discovery remains one of the most expensive and uncertain undertakings in modern science. Industry estimates suggest that it can take over a decade and billions of dollars to bring a single drug to market, with most candidates failing before clinical trials. A major bottleneck lies upstream, where target identification, compound screening and optimisation are often fragmented across tools, teams and datasets.

Nanyang Biologics’ approach departs from this convention. Rather than deploying standalone AI models to optimise isolated steps, the company has developed an integrated workflow that embeds artificial intelligence across the entire discovery process — from biological target selection to compound prioritisation — allowing researchers to make decisions with a unified, data-driven view .

This integrated philosophy has drawn the attention of global technology leaders. Nanyang Biologics was selected into the NVIDIA Ignition Accelerator, featured at multiple NVIDIA GTC conferences, and formally listed as an NVIDIA Partner — a validation of both its technical depth and its alignment with enterprise-grade AI infrastructure.

.

In August, the company took a further step by jointly signing a memorandum of understanding with NVIDIA, Hewlett-Packard Enterprise and Equinix to co-develop Vecura, an AI-powered drug discovery platform designed to operate at industrial scale. The collaboration brings together accelerated computing, secure cloud infrastructure and high-performance AI orchestration to support pharmaceutical-grade workloads .

At the core of Vecura is a proprietary AI engine that combines graph neural networks, molecular interaction modelling and nature-inspired compound libraries. According to published benchmarking, the platform has demonstrated materially higher prediction accuracy compared with leading conventional approaches, while reducing experimental cycles and false leads early in discovery — a critical lever for cost control in pharma R&D .

Beyond platform development, Nanyang Biologics is also advancing its own therapeutic pipeline in areas such as oncology, cardiovascular disease and mental health, using AI to uncover previously “undruggable” targets and novel mechanisms of action. This dual strategy — platform plus pipeline — allows the company to validate its technology internally while offering it externally to partners .

Founded in Singapore, Nanyang Biologics reflects the city-state’s ambition to become a regional nexus for deep-tech biomedical innovation. Through Vecura AI, the company aims to support large pharmaceutical firms by offering a more efficient, cost-effective and scalable approach to early-stage drug discovery — helping transform R&D from a high-risk art into a more predictable, data-driven science.

As pressure mounts on the global pharma industry to deliver better medicines faster and at lower cost, platforms like Vecura may signal how the next chapter of drug discovery will be written — with Singapore firmly in the story.

Read previous articles:

Decoding China Deeptech: 6D5N China Insight Programme

Winning Visibility in the AI Era: The Rise of Generative Engine Optimisation (GEO)